Cofoe Medical Technology Co., Ltd. has launched a Global Offering of 27.00 million H-shares ahead of its planned Main Board debut on the Hong Kong Stock Exchange (HKEX). The offer comprises 2.70 million shares (10%) for the Hong Kong Public Offering and 24.30 million shares (90%) for the International Offering, both subject to potential reallocation. In accordance with PN18 of the Listing Rules, up to 1.35 million shares may be shifted from the international tranche to the public tranche, lifting the public portion to a maximum 4.05 million shares (15% of the deal).

The maximum offer price is set at HK$39.33 per share. Based on this ceiling, gross proceeds could reach approximately HK$1.06 billion before deducting underwriting commissions and other expenses. Each share carries a nominal value of RMB1.00 and will trade in board lots of 100 under stock code 1187.

Key dates include: • Application period: 09:00 Monday, 27 April 2026 to 12:00 Thursday, 30 April 2026. • Price determination: no later than 12:00 Monday, 4 May 2026. • Allocation and pricing results announcement: by 23:00 Tuesday, 5 May 2026. • Expected first trading day: 09:00 Wednesday, 6 May 2026.

Applications are fully electronic. Investors may apply via the HK eIPO White Form service (www.hkeipo.hk) for share certificates registered in their names or through brokers/custodians using the HKSCC EIPO channel for CCASS deposits.

Huatai Financial Holdings (Hong Kong) Limited and BNP Paribas Securities (Asia) Limited act as Joint Sponsors, Sponsor-Overall Coordinators and Overall Coordinators; Futu Securities International (Hong Kong) Limited serves as an additional Overall Coordinator. Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers are named in the prospectus.

Listing remains subject to HKEX approval and customary conditions. Dealings in the H-shares will commence only after the Global Offering becomes unconditional; investors trading before receipt of share certificates bear settlement risk.